【摘要】 目的探讨去铁酮联合去铁胺治疗重症地中海贫血患儿的临床疗效。方法选择2013年7月到2017年12月期间中山市博爱医院儿科收治的60例重型地中海贫血患儿为研究对象,根据随机数表法将患儿分为观察组与对照组,每组30例,对照组予单独应用去铁胺治疗,观察组则联合应用去铁酮和去铁胺治疗,疗程12个月。比较两组患儿治疗后的临床疗效以及治疗前后不同时间患儿血清铁蛋白(SF)水平的变化。结果观察组患儿的治疗总反应率为83.33%,明显高于对照组的63.33%,差异有统计学意义(P<0.05);观察组患儿治疗后6个月、12个月血清SF水平分别为(2 260.7±204.8)μg/L、(1 986.6±215.8)μg/L,均明显低于对照组的(2 398.3±172.3)μg/L、(2 127.4±233.9)μg/L,差异均有统计学意义(P<0.05)。结论去铁酮联合去铁胺治疗重症地中海贫血患儿的去铁效果优于单用去铁胺,其可以尽快降低患儿的铁负荷,提高治疗反应率,且无明显不良反应。更多还原

【Abstract】 Objective To investigate the clinical efficacy of deferiprone combined with desferrioxamine in the treatment of children with severe thalassemia. Methods A total of 60 cases of children with severe thalassemia, who admitted to Department of Pediatrics of Zhongshan Humanity Hospital from July 2013 to December 2017, were selected and divided into the observation group and the control group according to random number table method, with 30 cases in each group. The control group was treated with desferrioxamine alone, while the observation group was treated with deferiprone combined with desferrioxamine for 12 months. The curative effect after treatment and the changes of serum ferritin(SF) levels in children before and after treatment at different time in the two groups were compared. Results The total response rate of the observation group was 83.33%, which was significantly higher than 63.33% of the control group(P<0.05); the serum SF of the observation group was(2 260.7±204.8) μg/L and(1 986.6±215.8) μg/L at 6 and 12 months after treatment, respectively, which were significantly lower than corresponding(2 398.3±172.3) μg/L and(2 127.4±233.9) μg/L of the control group(P<0.05). Conclusion The effect of deferiprone combined with desferrioxamine in the treatment of children with severe thalassemia is better than that of desferrioxamine alone. It can reduce the iron load of children as soon as possible and improve the response rate of treatment without obvious adverse reactions.更多还原